Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biocon Staying Firm On Insulins Path, Including Glargine

Executive Summary

Biocon has reported strong second-quarter earnings and underscored its interest in the insulins space, including insulin glargine, at least for now. Merck & Co recently called off plans to commercialize its Lantus version.

You may also be interested in...



Equillium Will Study In-Licensed Itolizumab In Three Indications In 2019

Emerging Company Profile: Equillium in-licensed the CD6 inhibitor EQ001 – Biocon's Alzumab (itolizumab), approved in India for psoriasis – and will begin clinical trials for three autoimmune disease indications this year; a Phase Ib/II aGvHD study is under way.

Biosimilars Begin To 'Pay Off' For Biocon

Biocon rang in a strong Q3, buoyed by the momentum in its biologics business. The firm appears undeterred by suggestions that the US biosimilars market may be less attractive than initially anticipated.

Key Wins In US By Indian Firms - Keep An Eye On These In 2019

2018 saw front-line Indian companies receive some key product approvals in the US or sew up large or niche M&A transactions there. How these play out could have a material impact on the growth outlook of these firms in 2019. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1123310

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel